Ulcerative Colitis and Crohn's DiseaseEntyvio PASSNCT02674308
Entyvio (Vedolizumab) Long Term Safety Study
An observational study of Ulcerative Colitis and Crohn's Disease, run by Takeda at 287 sites in 21 countries.
Trial summary
The purpose of this study is to assess the long-term safety of vedolizumab versus other biologic agents in participants with Ulcerative Colitis (UC) or Crohn's Disease (CD). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Ulcerative Colitis and Crohn's Disease
- What is being tested?
- Vedolizumab and Other Biologic Agents
- How many people
- 5,302 participants
- Where
- 287 sitesin 21 countries
- Study dates
- 24 Mar 2015to 30 Jul 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Participants with ulcerative colitis (UC) or Crohn's disease (CD) who are initiating Entyvio or another biologic agent. Participants may be biologic-naive or have prior use of a biologic agent
Who may be able to join
- Signed informed consent, by the participant or a legally acceptable representative.
- Aged at least 18 years.
- Initiating vedolizumab or another biologic agent for UC or CD.
- Signed release form, by the participant or a legally acceptable representative, permitting abstraction of the participant's medical records at Baseline and during participation in the study.
Who cannot join
- The participant is enrolled in a clinical trial in which treatment for CD or UC is managed through a protocol.
- Prior treatment with vedolizumab.
- Any other reason that, in the Investigator's opinion, makes the participant unsuitable to participate in this study.
Trial locations and contacts
287 sites in 21 countries.
287 sites in 21 countries
United States66 sites
University of Michigan
Ann Arbor, Michigan, 48109
Illinois Gastroenterology Groupllc Northwest Gastroenterologists
Arlington Heights, Illinois, 60005
Emory University Hospital, the Emory Clinic
Atlanta, Georgia, 30322
Atlanta Gastroenterology Associates
Atlanta, Georgia, 30342
Georgia Regents University
Augusta, Georgia, 30904
University of Alabama
Birmingham, Alabama, 35294
Crohn'S and Colitis Center
Boston, Massachusetts, 02114
Boston University Moakley Building Center For Digestive Disorders
Boston, Massachusetts, 02118
Saratoga-Schenectady Gastroenterology Associates
Burnt Hills, New York, 12027
University of North Carolina
Chapel Hill, North Carolina, 27599
Medical University of South Carolina
Charleston, South Carolina, 29425
University of Virginia Health System
Charlottesville, Virginia, 22908
Rush University Medical Center
Chicago, Illinois, 60612
University of Chicago Medical Center
Chicago, Illinois, 60637
Trihealth Digestive Institute
Cincinnati, Ohio, 45242
Consultants in Gastroenterology - Columbia
Columbia, South Carolina, 29203
Englewood Endoscopic Associates
Englewood, New Jersey, 07631
Northshore University Health Systems
Evanston, Illinois, 60201
Digestive Disease Center
Fishkill, New York, 12524
Study site
Fort Sam Houston, Texas, 78234
Infusion Associates, Grand Rapids
Grand Rapids, Michigan, 48525
Northwell Health
Great Neck, New York, 11021
Nyu Langone Long Island Clinical Research Associates
Great Neck, New York, 11021
Carolina Research
Greenville, North Carolina, 27834
Gastroenterology Center of Connecticut P.C.
Hamden, Connecticut, 06518
Baylor University Medical Center
Houston, Texas, 77030
Ut Health Science Center
Houston, Texas, 77030
Spring Gastroenterology
Humble, Texas, 77338
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242
The University of Kansas Medical Center
Kansas City, Kansas, 66160
Scripps Clinic
La Jolla, California, 92037
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, 03756
University of Louisville
Louisville, Kentucky, 40202
Loyola University
Maywood, Illinois, 53226
New Orleans Research Institute
Metairie, Louisiana, 70006
Middlesex Gastroenterology Associates, Llc
Middletown, Connecticut, 06457
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
University of South Alabama
Mobile, Alabama, 36688
Morristown Medical Center
Morristown, New Jersey, 07960
Gastroenterology Group of Naples
Naples, Florida, 34102
Vanderbilt University Medical Center
Nashville, Tennessee, 37232
Nyu Langone Medical Center
New York, New York, 10016
Icahn School of Medicine At Mount Sinai
New York, New York, 10029
Lenox Hill Hospital
New York, New York, 10075
Southwest Gastroenterology
Oak Lawn, Illinois, 60453
Digestive Health Center, Pa
Ocean Spring, Mississippi, 39564
Chi Health Alegent Creighton Clinic
Omaha, Nebraska, 68124
Florida Hospital Orlando
Orlando, Florida, 32803
Stanford University
Palo Alto, California, 94304
Gulf Region Clinical Research Institute
Pensacola, Florida, 32514
Mark Osterman
Philadelphia, Pennsylvania, 19104
Philadelphia Va Medical Center
Philadelphia, Pennsylvania, 19104
Wake Research Associates
Raleigh, North Carolina, 27612
Mayo Clinic - Rochester
Rochester, Minnesota, 55905
Gastroenterology Group of Rochester
Rochester, New York, 14618
Virginia Mason Medical Center
Seattle, Washington, 98101
Louisiana Research Center, Llc
Shreveport, Louisiana, 71106
St. Louis University
St Louis, Missouri, 63104
Washington University
St Louis, Missouri, 63110
Atlanta Gastroenterology Associates
Suwanee, Georgia, 30024
Cotton O'Neil Digestive Health Center
Topeka, Kansas, 66606
South Bay Gastroenterology Medical Group
Torrance, California, 90505
University of Arizona Medical Center
Tucson, Arizona, 85724
Kansas Gastroenterology
Wichita, Kansas, 67226
Wake Forest University School of Medicine
Winston-Salem, North Carolina, 27157
Umass Memorial Medical Center
Worcester, Massachusetts, 01655
Germany46 sites
Praxis Dr. Med. Eberhard Meier
Amberg, 92224
Charite Campus Campus Mitte
Berlin, 10117
Praxis Dr. Mross
Berlin, 10318
Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin (Cbf) - Medizinische Klinik I
Berlin, 12203
Charite Campus Virchow Klinikum - Medizinische Klinik Mit Schwerpunkt Hepatologie Und Gastroenterologie
Berlin, 13353
Praxis Fur Gastroenterologie Am Bayerischen Platz
Berlin, 14169
Sana Klinik Biberach
Biberach, 88400
Medizinisches Versorgungszentrum (Mvz) Dachau
Dachau, 85221
Stadtisches Klinikum Dessau
DESSAU-ROsLAU, 06847
Technische Universitaet Dresden - Universitaetklinikum Carl Gustav Carus - Medizinische Klinik Und Poliklinik I
Dresden, 01307
Universitatsklinikum Erlangen Medizinische Klinik I - Studien Ambulanz Ced
Erlangen, 91054
St. Josef Krankenhaus Essen-Werden / Abteilung Fur Gastroenterologie
Essen, 45239
Agaplesion Markus Krankenhaus, Medizinische Klinik 1
Frankfurt, 60431
Crohn-Colitis Centrum Rhein-Main
Frankfurt am Main, 60594
Praxis Dr. Med. Thomas Zeisler
Halle, 06108
Krankenhaus Martha-Maria Halle Dolau Ggmbii, Klinik Fur Innere Medizin I
Halle, 06120
Universitatsklinik Und Poliklinik Fur Innere Medizin I
Halle, 06120
Asklepios Westklinikum Hamburg
Hamburg, 22559
Hafced E.K.
Hamburg Eppendorf, 20251
Universitatsklinikum Heidelberg
Heidelberg, 69120
Praxis Fur Gastroenterologie
Heidelberg, 69121
Gastroenterologische Gemeinschaftspraxis Dr. Felten
Herne, 44623
Praxis Group
Jerichow, 39319
PRAXIS
Köthen, 06366
Eugastro Gmbh
Leipzig, 04103
Universitat Leipzig, Medizinische Fakultat
Leipzig, 04103
Gesellschaft Fuer Klinische Studien
Leipzig, 04105
St. Marien Krankenhauses - Medizinischen Klinik I
Ludwigshafen am Rhein, 67067
Staedtisches Klinikum Luneburg
Lüneburg, 21339
Universitatsklinikum Magdeburg A. O. R. - Klinik Fur Gastroenterologie
Magdeburg, 39120
Universitaetsmedizin Mainz, I.Med.Klinik, Geb.605, Eg, Zi.0240
Mainz, 55131
Gastroenterologische Schwerpunkt Praxis
Mannheim, 68161
Praxis Dr. Krammer
Mannheim, 68165
Universitaetsklinikum Mannheim (Umm) - Ii Medizinische Klinik
Mannheim, 68167
Gastroenterologische Gemeinschaftspraxis Minden
Minden, 32423
Klinikum Der Universitat Munchen
München, 81377
Medizinische Versorgungszentrum Portal 10
Münster, 48155
Gastroenterologische Fachpraxis Am Germania Campus
Münster, 48159
Praxis Group
Nuremberg, 90449
Praxiszentrum Alte Malzerei
Regensburg, 93053
Eric Norgaard Jorgensen
Remscheid, 42859
Gpr Mvz Gastroenterologie
Rüsselsheim am Main, 65428
Gemeinschaftspraxis - Endoskopiezentrum M. Hasenstein
Saarbrücken, 66113
Gastroenterologische Gemeinschaftspraxis - Stade
Stade, 21682
Uni-Klinik Tubingen
Tübingen, 72076
Gastro Data Gbr
Wiesbaden, 65189
United Kingdom25 sites
Nevill Hall Hospital - Aneurin Bevan Health Board
Abergavenny, NP7 7EG
Blackpool Victoria Hospital (Bvh) - Gastroenterology Department
Blackpool, FY3 8NR
Bradford Teaching Hospitals
Bradford, BD9 6RJ
Frimley Park Hospital
Camberley, GU14 7UJ
University Hospitals Coventry and Warwickshire Nhs Trust - University Hospital (Walsgrave Hospital)
Coventry, CV2 2DX
Derby Hospitals Nhs Foundation Trust - Royal Derby Hospital (Derby City General Hospital)
Derby, DE22 3NE
The North West London Hospitals Nhs Trust (Nwlh) - St Mark'S Hospital
Harrow, HA1 3UJ
Hull and East Yorkshire Nhs Trust
Hull, HU32JZ
Airedale Nhs Foundation Trust
Keighley, BD20 6TD
Forth Valley Royal Hospital
Larbert, FK5 4WR
Royal Liverpool University Hospital
Liverpool, L7 8XP
Barts Health Nhs Trust
London, E11 1NR
Nhs Foundation Trust - Homerton University Hospital (Huh)
London, E9 6SR
King'S College Hospital (Kch) Nhs Foundation Trust
London, SE5 9RS
Manchester Royal Infirmary
Manchester, M13 9WL
Royal Gwent Hospital
Newport, NP20 2UB
The University of Nottingham - Nottingham Digestive Diseases Centre (Nddc) (Wolfson Digestive Diseases Centre)
Nottingham, NG7 2UH
Salford Royal Nhs Foundation Trust
Salford, M6 8HD
University of Sheffield - Sheffield Teaching Hospitals Nhs Foundation Trust - Royal Hallamshire Hospital (Rhh)
Sheffield, S10 2JF
The Shrewsbury and Telford Hospital Nhs Trust - Royal Shrewsbury Hospital
Shrewsbury, SY3 8XQ
University Hospital Southampton Nhs Foundation Trust
Southampton, SO16 6YD
Pinderfields Hospital - Mid Yorkshire Hospital Trust
Wakefield, WF1 4DG
Nhs Trust - Weston Area Health - Weston General Hospital
Weston-super-Mare, BS23 4TQ
The Royal Wolverhampton Hospitals Nhs Trust - New Cross Hospital
Wolverhampton, WV6 9AT
Western Sussex Hospitals Nhs Trust - Worthing Hospital
Worthing, BN11 2DH
France24 sites
Chu Amiens Picardie - Service Hepato-Gastro-Enterologie
Amiens, 80054
C H U Angers
Angers, 49033
Hopital Avicenne
Bobigny, 93000
Centre Hospitalier Universitaire (Chu) de Caen - Service D'Hepatogastroenterologie
Caen, 14033
C.H.U de Tours - Hopital Trousseau
Chambray-lès-Tours, 37170
Chu de Clermont Ferrand - Hopital Estaing
Clermont-Ferrand, 63000
Hopitaux Civils de Colmar
Colmar, 68024
Centre Hospitalier Regional Universitaire (Chru) de Lille - Hopital Claude Huriez
Lille, 59037
Hospices Civils de Lyon (Hcl) - Hopital Edouard Herriot
Lyon, 69003
Chu Hopital Nord, Marseille - Service D'Hepato-Gastro-Enterologie
Marseille, 13015
University Hospital St Eloi
Montpellier, 34295
Centre Hospitalier Universitaire (Chu) de Nice - Hopital L'Archet 2 - Pole Digestif
Nice, 06202
Chu Nimes - Hopital Caremeau
Nîmes, 30029
Centre Hospitalo Universitaire (Chu) - Hopital Saint-Antoine
Paris, 75012
Institut Mutualiste Montsouris
Paris, 75674
Hopital Du Haut Leveque - Service D'Hepato-Gastro-Enterologie Et Nutritution, Unite de Soin Normalise
Pessac, 33604
Hospices Civils de Lyon (Hcl) - Centre Hospitalier Lyon-Sud - Hepatogastroenterologie
Pierre-Bénite, 69495
Centre Hospitalier Annecy Genevois
Pringy, 74374
Chu de Reims - Hopital Robert Debre
Reims, 51100
Centre Hospitalier Universitaire (Chu) de Rouen
Rouen, 76031
Service Gastro-Enterologie Hopital Nord - Chu de Saint Etienne
Saint-Etienne, 42000
Hopital Rangueil - Service de Gastroenterologie
Toulouse, 31059
Ch Gustave Dron - Hopital de Tourcoing
Tourcoing, 59208
Ch Valenciennes - Hopital Jean Bernard - Service Maladies de L'Appareil Digestif Et de La Nutrition
Valenciennes, 59322
Italy24 sites
Ospedale Civile Giuseppe Moscati
Avellino Campania, 83100
Spedali Civili Gastroenterology Unit University of Brescia
Brescia, 25123
Fondazione Poliambulanza
Brescia, 25124
Azienda Ospedaliera Per Lemergenza Cannizzaro
Catania, 95126
Azienda Ospedaliero-Universitaria Careggi (Aouc)
Florence, 50134
Casa Sollievo Della Sofferenza
Foggia, 71013
Ospedale Morgagni Pierantoni Forli U.O. Gastroenterologia Ed Endoscopia
Forlì, 47121
Policlinico G Martino
Messina, 98125
A.O. Guido Salvini Di Garbagnate Milanese
Milan, 20017
Fondazione Irccs Ca' Granda Osp Magg Policlinico
Milan, 20122
Asst Fatebenefratelli Sacco
Milan, 20157
Universita Federico Ii
Naples, 80131
Ospedale Maggiore Della Carita
Novara, 28100
Policlicnico Universita Paolo Giaccone
Palermo, 90127
Ao San Camillo Forlanini
Roma, 00152
Ospedale Nuovo Regina Margherita
Roma, 00153
Ospedale Sandro Pertini
Roma, 00157
Fondazione Policlinico Universitario A. Gemelli
Roma, 00168
Ospedale San Filippo Neri
Roma
Universita Campus Bio-Medico
Rome, 00128
Policlinico Tor Vergata
Rome, 00133
Universita Di Salerno Aou San Giovanni Di Dio E Ruggi D'Aragona
Salerno, 84100
Ao Ordine Mauriziano Di Torino
Torino, 10128
Osp Di Circolo Fondazione Macchi
Varese, 21100
Belgium23 sites
Olv Aalst - Gastro-Enterologie
Aalst, 9300
Imelda - Gastro-Enterologie
Bonheiden
Chu Saint Pierre - Service de Gastroenterologie
Brussels, 1000
Cub Hopital Erasme
Brussels, 1070
HIS-IZZ
Brussels, 1070
Uz Brussel - Gastro-Enterologie
Brussels, 1090
Uz Antwerpen - Gastro-Enterologie
Edegem, 2650
Ziekenhuis Oost Limburg - Gastro-Enterologie
Genk, 3600
Az Maria Middelares - Gastro-Enterologie
Ghent, 9000
Az St Lucas - Gastro-Enterologie
Ghent, 9000
Uz Gent - Gastro-Enterologie
Ghent, 9000
Jessa Ziekenhus - Gastro-Enterologie
Hasselt, 3500
Az Groeninge - Campus Kennedylaan - Gastro-Enterologie
Kortrijk, 85000
Universitaire Ziekenhuizen (Uz) Leuven - Gasthuisberg
Leuven, 3000
Centre Hospitalier Chretien (Chc) - Clinique Saint-Joseph (Hopital St-Joseph) - Gastro-Enterologie
Liège, 4000
Chr de La Citadelle
Liège, 4000
Chu Liege - Gastro-Enterologie
Liège, 4000
Az Sint Maarten, Campus Rooienberg
Mechelen, 2800
Chu Ambroise-Pare
Mons, 7000
Clinique Et Maternite Sainte-Elisabeth
Namur, 5000
Clinique St Pierre Asbl
Ottignies, 1340
Az Delta - Gastro-Enterologie
Roeselare, 8800
Centre Hospitalier de Wallonie Picardie, Site Notre Dame
Tournai, 7500
Israel11 sites
Haemek Medical Center
Afula, 18341
Soroka University Medical Center (Sumc)
Beersheba, 84101
Rambam Health Care Campus (Rhcc) - Institute of Gastroenterology
Haifa, 3.1096E+006
Bnai Zion Mc
Haifa, 3339510
Clalit Health Services - Lev Talpiot
Jerusalem, 9362410
Meir Medical Center
Kfar Saba, 44281
Tel Aviv University - Rabin Medical Center - Beilinson Hospital
Petah Tikva, 49100
Clalit Medical Services - Migdal Hamea
Tel Aviv, 6203854
Maccabi Healthcare Services
Tel Aviv
Tel Aviv Medical Center
Tel Aviv
Assaf Harofeh Medical Center (Ahmc) - Institute of Gastroenterology
Zrifin, 70300
Austria8 sites
Krankenhaus Der Elisabethinen Linz Gmbh
Oberosterreich, 4020
Kh Der Barmherzigen Schwestern
Ried im Innkreis, 4910
Ordination Dr. Thomas Haas Darmpraxis Salzburg
Salzburg, 5020
Salk Salzburg
Salzburg, 5020
Landesklinikum St. Poelten
Sankt Pölten, 3100
Medizinischen Universitat Wien - Allgemeines Krankenhaus (Akh) - Universitaetsklinik Fuer Innere Medizin Iii
Vienna, 1090
Loha For Life
Vienna, 1190
KH WELS
Wels, 4600
Canada7 sites
Nova Scotia Health Authority
Halifax, Nova Scotia, B3H2Y9
McMasters University
Hamilton, Ontario, L8S 4K1
Okanagan Clinical Trials Ltd.
Kelowna, British Columbia, V1Y 1Z9
Scott Shulman Medical Prof. Corp
North Bay, Ontario, P1B 2H3
Taunton Surgical Centre-Oshawa Clinic
Oshawa, Ontario, L1H 7K4
Royal University Hospital
Saskatoon, Saskatchewan, S7N 0W8
University of Toronto - St. Michaels Hospital
Toronto, Ontario, M5B 1W8
Greece7 sites
University and General Hospital of Alexandroupoli
Alexandroupoli, 68100
General Hospital of Athens 'Evangelismos'
Athens, 10676
General and University Hospital of Western Athens 'Attiko'
Athens, 12462
St. Panteleimon General Hospital of Nikaia
Athens, 18454
University and General Hospital of Heraklion
Heraklion, 71110
University Hospital of Ioannina - Division of Gastroenterology
Ioannina, 45110
Theagenio Hospital of Thessaloniki
Thessaloniki, 54639
Netherlands7 sites
VUMC
Amsterdam, 1007 MB
Onze Lieve Vrouwe Gasthuis
Amsterdam, 1091 AC
Academisch Medisch Centrum - Mdl
Amsterdam, 1105 AZ
Amphia Ziekenhuis
Breda, 4818 CK
Albert Schweitzer Ziekenhuis
Dordrecht, 3300 AK
Erasmus Mc
Rotterdam, 3000 CA
Zuyderland
Sittard, 6162 BG
Denmark6 sites
University Hospital, Aalborg
Aalborg, 9000
Rigshospitalet, Abdominal Centre
Copenhagen, DK-2100
Bispebjerg Univarsity Hospital
Copenhagen NV, 2400
Hvidovre Hospital
Hvidovre, 2650
Nykobing Falster Sygehus
Nykøbing Falster, 4800
Silkeborg Hospital
Silkeborg, 8600
Ireland6 sites
Mercy University Hospital Cork
Cork
Beaumont Hospital
Dublin, 9
Mater Misericordiae University Hospital
Dublin
St James Hospital
Dublin
St. Vincent'S University Hospital
Dublin
National University of Ireland Galway
Galway
Spain6 sites
Hospital Univ. Germans Trias I Pujol
Badalona, 08916
Hospital de Bellvitge
Hospitalet, 08907
Hospital Universitario La Paz
Madrid, 28046
Complexo H. Pontevedra-Hospital de Montecelo
Pontevedra, 36164
Consorci Sanitari de Terrassa
Terrassa, 08227
H. Alvaro Cunqueiro
Vigo, 36312
Croatia4 sites
University Hospital Center Osijek
Osijek, 31000
Clinical Hospital Centre Split
Split, 21000
Kbc Split
Split, 21000
University Hospital Dubrava
Zagreb, 10000
Norway4 sites
Nordlandssykehuset Hf Bodo
Bodø, 8092
Sykehuset Innlandet Hf Hamar
Hamar, 2326
Akershus University Hospital
Nordbyhagen, 1478
Oslo Univeristy Hospital Ulleval Hospital
Oslo, 0424
Switzerland4 sites
Universitaetsspital Bern - Inselspital - Universitaetsklinik Fuer Viszerale Chirurgie Und Medizin (Uvcm) - Klinik Und Poliklinik Fuer Gastroenterologie
Bern, 3010
Gastroenterologische Praxis Balsiger, Seibold & Partner Crohn-Colitis-Zentrum Hochhaus Lindenhofspital
Bern, 3012
Kantonsspital St. Gallen - Gastroenterologie
Sankt Gallen, 9007
Universitatspital Zurich
Zurich, 8091
Estonia3 sites
West-Tallinn Central Hospital (Ltkh)
Tallinn, 10617
North Estonian Regional Hospital
Tallinn, 13419
Tartu University Hospital
Tartu, 51014
Sweden3 sites
Medical Dept, Gastroenterology Unit
Stockholm, 11281
Karolinska Universitetssjukhuset Huddinge
Stockholm, 14186
Danderyds Sjukhus Ab
Stockholm, 182 88
Slovenia2 sites
General Hospital Celje
Celje, 3000
University Medical Center Maribor
Maribor, 2000
Portugal1 site
Instituto Portugues de Oncologia de Lisboa Francisco Gentil, Epe
Lisbon, 1099-023
About this study
Official title: Entyvio (Vedolizumab) Long-term Safety Study: An International Observational Prospective Cohort Study Comparing Vedolizumab to Other Biologic Agents in Patients With Ulcerative Colitis or Crohn's Disease
The purpose of this study is to assess the long-term safety of vedolizumab versus other biologic agents in participants with Ulcerative Colitis (UC) or Crohn's Disease (CD).
Read the detailed description
The drug being tested in this prospective, observational study is called vedolizumab. Vedolizumab is being used to treat people who have UC or CD. This study will look at the long-term safety of vedolizumab versus other biologic agents in participants with UC or CD. The study will enroll approximately 5000 participants. All participants enrolled in this will belong to one of the two treatment group:
- Vedolizumab
- Other Biologic Agents -adalimumab, certolizumab pegol.
Golimumab and infliximab. Study drugs will be prescribed by the physician according to local prescribing information in the participating countries. This multi-centre trial will be conducted worldwide. The overall time to participate in this study is 7 years. Participants will make visits at every 6 months to their treating physician.
- Conditions
- Ulcerative Colitis and Crohn's Disease
- Being tested
- Vedolizumab, Other Biologic Agents
- Keywords
- Drug therapy
- Medical subject headings
- Colitis, Ulcerative, Crohn Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
VedolizumabDrug
Other Biologic AgentsOther
Other biologic agents include: Adalimumab, Certolizumab pegol, Golimumab, and Infliximab
| Study group | Role | What they receive |
|---|---|---|
| Vedolizumab | Not described Receives: Drug: Vedolizumab | |
| Other Biologic Agents | Not described Receives: Other: Other Biologic Agents |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants with Adverse Events of Special Interest
Adverse events of special interest in this study includes serious and opportunistic infections, gastrointestinal infections, respiratory infections, other clinically significant infections: malignancies; infusion-related reactions and hypersensitivity, hepatic injury; psoriasis and other skin events, other SAEs and adverse reactions.
Measured: 7 years
Secondary outcomes (6)
Disease Severity in Ulcerative Colitis (UC) Participants
Disease severity will be measured using the Mayo score for ulcerative colitis and is ranged from 0 (normal or inactive disease) to 9 (severe disease) and calculated as the sum of 3 subscores: stool frequency, rectal bleeding and physician rating of disease activity, each ranged from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe).
Measured: Baseline and at every 6 months (up to 7 years)
Disease Severity in Crohn's Disease (CD) Participants
Disease severity will be measured using the Harvey-Bradshaw Index (HBI) for crohn's disease. HBI is used in the assessment and quantification of symptoms and the present level of disease activity of participants with Crohn's disease. It is a validated clinical index for Crohn's disease,HBI score consists of clinical parameters of general well-being (0= very well 1=slightly below average, 2=poor, 3=very poor, 4=terrible); abdominal pain (0=none, 1=mild, 2=moderate, 3=severe); number of liquid stools per day; abdominal mass (0=none, 1=dubious, 2=definite, 3=tender); and complications (8 items: arthralgia, uveitis, erythema nodosum, aphthous ulcers, pyoderma gangrenosum, anal fissures, new fistula, abscess [score 1 per item]).Lower scores indicate better well-being. The scores are classified as: <5=remission, 5-7=mild disease, 8-16=moderate disease and >16=severe disease. Minimum score is 0 and no pre-specified maximum score as it depends on the number of liquid stools.
Measured: Baseline and at every 6 months (up to 7 years)
Participant Reported Quality of Life Assessment Using Short Inflammatory Bowel Disease Questionnaire (SIBDQ)
The Short IBD Questionnaire is an instrument used to assess quality of life and is a disease-specific health-related quality of life questionnaire, that consists of 10 questions, each question is scored on a scale from 1 (poor quality of life) to 7 (good quality of life). The scores are summed up and divided by 10 for a mean score ranging from 1 (poor quality of life) to 7 (good quality of life). A higher score indicates a better health-related quality of life.
Measured: Baseline and at every 6 months (up to 7 years)
Participant Reported Quality of Life Assessment Using 12-Item Short Form Health Survey (SF-12)
The SF-12 health questionnaire is a 12 question assessment of functional health and well-being. The survey asks about various health aspects, including physical functioning, role limitations due to physical health problems, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health (psychological distress and psychological well-being). Two summary measures are derived: the Physical and the Mental Health Component Summary. For each component summary, survey items were weighted and summed to create a summary score between 0 and 100 with higher score indicating better quality of life.
Measured: Baseline and at every 6 months (up to 7 years)
Time to Treatment Discontinuation
Time to discontinuation for Entyvio and the other biologic agents will be measured.
Measured: Baseline and at every 6 months (up to 7 years)
Reasons for Treatment Discontinuation
Reasons for discontinuations for Entyvio and the other biologic agents will be measured.
Measured: Baseline and at every 6 months (up to 7 years)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Feb 2016 (estimated)
- Study start24 Mar 2015
- Primary completion30 Jul 2021
- Study completion30 Jul 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ulcerative Colitis and Crohn's DiseaseStudies of the same condition, open and under way.
- More trials run by TakedaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 5,302 participants (actual)
Sponsor and investigators
- Lead sponsor
- Takeda
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Medical Director, Study director, Takeda
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02674308
- Sponsor's protocol ID
- MLN-0002_401
- Other IDs
- MLN0002-401
- Acronym
- Entyvio PASS
- Status last verified
- Oct 2024
- First submitted
- 29 Jan 2016
- Last updated
- 31 Oct 2024
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- Yes: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Study at a glance
From the registry record, last updated by the sponsor on 31 Oct 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Entyvio (Vedolizumab) Long-term Safety Study: An International Observational Prospective Cohort Study Comparing Vedolizumab to Other Biologic Agents in Patients With Ulcerative Colitis or Crohn's Disease
- ClinicalTrials.gov ID
- NCT02674308
- Acronym / sponsor ID
- Entyvio PASS / MLN-0002_401
- Conditions
- Ulcerative Colitis and Crohn's Disease
- Keywords
- Drug therapy
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 5,302 participants (actual)
- Lead sponsor
- TakedaIndustry (pharma, biotech, devices)
- Study start
- 24 Mar 2015 (actual)
- Primary completion
- 30 Jul 2021 (actual)
- Study completion
- 30 Jul 2021 (actual)
- First posted
- 4 Feb 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to assess the long-term safety of vedolizumab versus other biologic agents in participants with Ulcerative Colitis (UC) or Crohn's Disease (CD).
Detailed description
The drug being tested in this prospective, observational study is called vedolizumab. Vedolizumab is being used to treat people who have UC or CD. This study will look at the long-term safety of vedolizumab versus other biologic agents in participants with UC or CD. The study will enroll approximately 5000 participants. All participants enrolled in this will belong to one of the two treatment group:
- Vedolizumab
- Other Biologic Agents -adalimumab, certolizumab pegol.
Golimumab and infliximab. Study drugs will be prescribed by the physician according to local prescribing information in the participating countries. This multi-centre trial will be conducted worldwide. The overall time to participate in this study is 7 years. Participants will make visits at every 6 months to their treating physician.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Vedolizumab | – | Drug: Vedolizumab |
| Other Biologic Agents | – | Other: Other Biologic Agents |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Participants with ulcerative colitis (UC) or Crohn's disease (CD) who are initiating Entyvio or another biologic agent. Participants may be biologic-naive or have prior use of a biologic agent
Key inclusion criteria (4 listed)
- Signed informed consent, by the participant or a legally acceptable representative.
- Aged at least 18 years.
- Initiating vedolizumab or another biologic agent for UC or CD.
- Signed release form, by the participant or a legally acceptable representative, permitting abstraction of the participant's medical records at Baseline and during participation in the study.
Key exclusion criteria (3 listed)
- The participant is enrolled in a clinical trial in which treatment for CD or UC is managed through a protocol.
- Prior treatment with vedolizumab.
- Any other reason that, in the Investigator's opinion, makes the participant unsuitable to participate in this study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Vedolizumab | Drug | Vedolizumab |
| Other Biologic AgentsOther biologic agents include: Adalimumab, Certolizumab pegol, Golimumab, and Infliximab | Other | Other Biologic Agents |
Primary outcome
Percentage of Participants with Adverse Events of Special Interest
Time frame: 7 years
Adverse events of special interest in this study includes serious and opportunistic infections, gastrointestinal infections, respiratory infections, other clinically significant infections: malignancies; infusion-related reactions and hypersensitivity, hepatic injury; psoriasis and other skin events, other SAEs and adverse reactions.
6 secondary outcomes
Disease Severity in Ulcerative Colitis (UC) Participants
Time frame: Baseline and at every 6 months (up to 7 years)
Disease Severity in Crohn's Disease (CD) Participants
Time frame: Baseline and at every 6 months (up to 7 years)
Participant Reported Quality of Life Assessment Using Short Inflammatory Bowel Disease Questionnaire (SIBDQ)
Time frame: Baseline and at every 6 months (up to 7 years)
Participant Reported Quality of Life Assessment Using 12-Item Short Form Health Survey (SF-12)
Time frame: Baseline and at every 6 months (up to 7 years)
Time to Treatment Discontinuation
Time frame: Baseline and at every 6 months (up to 7 years)
Reasons for Treatment Discontinuation
Time frame: Baseline and at every 6 months (up to 7 years)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Oct 2024.
- To obtain more information on the study, click here/on this linkLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Related trials for Ulcerative Colitis and Crohn's Disease
RecruitingObservational study
Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
Inflammatory Bowel Disease, Crohn's Disease
Enrolling by invitationPhase 4
INSIGHT-IBD Pragmatic Study
Ulcerative Colitis (UC), Crohn Disease (CD)
RecruitingPhase 4
A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
Ulcerative Colitis, Crohn's Disease
Recruiting
Bacillus Probiotic Spores in Supporting the Treatment of Chronic Inflammatory Bowel Disease
Crohn Disease and Ulcerative Colitis
Not yet recruitingPhase 1
Study of Single and Multiple Ascending Doses of CM551 in Healthy Participants
Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Medical Director study director
Takeda
287 sites in 21 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Ulcerative Colitis and Crohn's Disease, run by Takeda at 287 sites in 21 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 31 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 287 sites in United States, Germany, United Kingdom, France, Italy and 16 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants with Adverse Events of Special Interest (time frame: 7 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Oct 2024; AzTrials last refreshed its copy on 30 Oct 2026.